The 4-Year Gap in Autism Care Deserves More Attention
For many families, the autism care journey begins long before a formal diagnosis.
It may start with a parent noticing that their child is not making eye contact, responding to their name, not using words as expected, has lost skills they once had, or seems to interact with the world in a different way. Sometimes the concern comes from a pediatrician, grandparent, teacher, or early childhood provider. Other times, it begins as a quiet feeling that something needs more attention.
But for too many families, early concern does not immediately lead to clear clinical answers or timely support.
Autism spectrum disorder can sometimes be detected by 18 months of age or younger, and by age 2, a diagnosis by an experienced professional can be considered reliable. The American Academy of Pediatrics recommends developmental and behavioral screening at 9, 18, and 30 months, as well as autism-specific screening at 18 and 24 months. Yet many children do not receive a final diagnosis until much later.1 According to the most recent CDC data from 2025, the median age of a child’s first autism diagnosis until close to age 4, with variation across communities.3
This is the “4-year gap” in autism care: the reality that many families are navigating developmental concerns, screening, referrals, waitlists, and uncertainty while many children still do not receive a documented autism diagnosis until the age of 4 or later.
That gap needs to be closed!
Autism Is Common, but the Path to Answers Is Still Too Slow
Autism affects a meaningful and growing number of families. According to CDC estimates, about 1 in 31 children in the United States have been identified with autism spectrum disorder by the age of 8.2,3 In the CDC’s California surveillance site, prevalence was even higher, about 1 in 19 children overall and about 1 in 12 boys, underscoring the growing need for earlier insight, education, and support.
While autism awareness has improved significantly over the past two decades, awareness alone does not solve the practical challenges families face. A child may be screened, referred, placed on a waitlist, evaluated, referred again, and then asked to wait months, sometimes longer, before services can be accessed.
For parents and caregivers, those months can feel like a never-ending odyssey. They are often navigating uncertainty while trying to make the best decisions for their child. They may wonder whether they should wait for a formal diagnosis before seeking therapy, whether their concerns are significant enough to push for further evaluation, or whether they are missing a critical window for support that could impact their child’s development.
For providers, the challenges are real as well. Primary care clinicians are often the first point of contact, but they may be working with limited visit time, long referral queues, and uneven access to developmental specialists. Autism itself is also highly heterogeneous, meaning children can present in very different ways. Some children have clear developmental delays early on, while others may show subtler social communication differences, sensory differences, behavioral changes, or regression over time.
The result is not one single delay, but a collection of delays that add up.
Why Closing the Gap Matters
The goal of earlier identification is not to rush families into labels or reduce a child to a diagnosis. It is to help families access information, support, and care sooner.
Early support can matter because the first years of life are a period of rapid development. Eunice Kennedy Shriver National Institute of Child Health (NICHD) notes that early diagnosis and intervention for autism are more likely to have major long-term positive effects on symptoms and later skills, and that early intervention programs may include family training, speech therapy, hearing-related services, physical therapy, nutrition services, and other developmental supports.4
Importantly, families do not always need to wait for every answer before beginning support. NICHD also notes that recent guidelines suggest starting integrated developmental and behavioral intervention as soon as autism is diagnosed or seriously suspected.4
That distinction is impactful. When a child is showing developmental concerns, waiting months or years for diagnostic certainty before beginning support may mean losing valuable time. Families deserve a care pathway that helps them act earlier, even while evaluation is still underway.
Earlier answers can help families:
Seek developmental and behavioral supports sooner
Access speech, occupational, or early intervention services
Better understand their child’s needs
Prepare for educational and care planning
Reduce uncertainty and anxiety
Have more informed conversations with providers
For providers, earlier identification can also support more informed triage. When waitlists are long, additional information can help determine which children may need more urgent evaluation or support.
What Contributes to the 4-Year Gap?
Several factors contribute to the gap between early concern and meaningful care growing longer:
Families are often told to “wait and see.” Some developmental differences become clearer over time, but repeated reassurance without structured follow-up can delay evaluation.
Screening does not always lead to action. A screening tool can identify concern, but it does not diagnose autism. If screening is not paired with referral, follow-up, or care coordination, families may still be left without a path forward.
Specialist waitlists are too long. Developmental pediatricians, child psychologists, and autism diagnostic centers often have limited availability. This can delay formal diagnosis even when concerns are recognized early.
Autism presents differently across children. Some children may have more obvious early signs. Others may have more subtle symptoms, co-occurring developmental concerns, or profiles that are harder to identify.
Access is uneven. CDC data show substantial variability in autism identification across communities, suggesting differences in service availability, evaluation practices, and early detection systems.3
Together, these factors can leave families in a difficult middle ground: concerned enough to seek answers, but not yet connected to the right supports.
Scientific Breakthrough Discovery Can Bridge the Gap
Autism does not arise by one single biological pathway. It is a heterogeneous condition, with many potential contributing factors and a wide range of developmental profiles and severity. That is why the discovery of biologic subtypes of autism is critical.
One area with over 20 years of published research is Maternal Autoantibody-Related Autism, or MARA.
MARA refers to one biologic subtype associated with specific patterns of maternal autoantibodies that react to proteins expressed in the developing brain. In a published study, researchers described maternal autoantibody-related autism as an immune mediated subtype of autism and reported specific patterns associated with autism.5 Majority of individuals with the MAR-Autism subtype require increased support in areas such as communication, behavior, and daily functioning. Peer-reviewed research shows that most individuals had ADOS scores >6 at the time of diagnosis.
MARAbio offers the MAR-Autism™ Test, which is designed to identify this MARA-associated subtype through a blood test in the mother. For families, the test provides the earliest answers possible into whether a child has over 97% risk of MARA, even before pregnancy and before autism-related symptoms are fully apparent in a child, helping families and providers consider family planning, earlier monitoring, referral, and treatment. The MAR-Autism™ Test provides important biological context to a clinical autism evaluation into the likely cause of a child’s autism and informs a more personalized care pathway for a child.
For families, biologic insight provides additional answers and for providers, it supports earlier conversations about family planning, developmental monitoring, referral, and care planning. For the field, it points toward a future where autism care may become more personalized, informed by underlying biology, and lead to treatments to mitigate the severity of a child’s symptoms.
Closing the Gap Requires Action
Awareness is important, but action is required.
To reduce the 4-year gap in autism care, families and providers need clear, practical pathways from concern to cause to action. That means encouraging earlier testing, developmental monitoring, taking parent concerns seriously, using recommended screening intervals, making referrals earlier, and helping families access support while they wait for formal evaluation.
It also means continuing to educate both families and healthcare providers about the evolving science of autism, including biologic subtypes such as MARA.
The goal is to get answers.
The goal is to help families understand their child’s needs and access support earlier.
The goal is earlier diagnosis, earlier connection, and earlier care.
For too long, families have been asked to wait while concerns grow, referrals stall, and developmental windows pass. The 4-year gap in autism needs to be closed, because every family deserves a clearer path forward.
References
1. Centers for Disease Control and Prevention. Screening for Autism Spectrum Disorder. Autism Spectrum Disorder (ASD). Updated April 15, 2025. Accessed July 8, 2026. https://www.cdc.gov/autism/diagnosis/index.html
2. Centers for Disease Control and Prevention. Data and Statistics on Autism Spectrum Disorder. Autism Spectrum Disorder (ASD). Updated May 27, 2025. Accessed July 8, 2026. https://www.cdc.gov/autism/data-research/index.html
3. Shaw KA, Williams S, Patrick ME, et al. Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years — Autism and Developmental Disabilities Monitoring Network, 16 Sites, United States, 2022. MMWR Surveillance Summaries. 2025;74(2):1–22. https://www.cdc.gov/mmwr/volumes/74/ss/ss7402a1.htm
4. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Early Intervention for Autism. Accessed July 8, 2026. https://www.nichd.nih.gov/health/topics/autism/conditioninfo/treatments/early-intervention
5. Ramirez-Celis A, Becker M, Nuño M, et al. Risk assessment analysis for maternal autoantibody-related autism (MAR-ASD): a subtype of autism. Molecular Psychiatry. 2021;26:1551–1560. https://doi.org/10.1038/s41380-020-00998-8